235 related articles for article (PubMed ID: 37316442)
1. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
[TBL] [Abstract][Full Text] [Related]
2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
4. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
[TBL] [Abstract][Full Text] [Related]
5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
6. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
Liu J; Xiang Y; Fang T; Zeng L; Sun A; Lin Y; Lu K
Clin Lung Cancer; 2024 Mar; 25(2):100-108. PubMed ID: 38172024
[TBL] [Abstract][Full Text] [Related]
9. [Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):179-188. PubMed ID: 38494765
[TBL] [Abstract][Full Text] [Related]
10. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Viteri S; Minchom A; Bazhenova L; Ou SI; Bauml JM; Shell SA; Schaffer M; Gu J; Rose JB; Curtin JC; Mahadevia P; Girard N
Mol Oncol; 2023 Feb; 17(2):230-237. PubMed ID: 36269676
[TBL] [Abstract][Full Text] [Related]
11. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
12. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies
in Non-small Cell Lung Cancer].
Wang Y; Chu T
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Outcomes for Patients with
Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
[TBL] [Abstract][Full Text] [Related]
16. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
[TBL] [Abstract][Full Text] [Related]
17. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
Chen H; Hu S; Patterson AV; Smaill JB; Ding K; Lu X
J Med Chem; 2023 Sep; 66(17):11656-11671. PubMed ID: 37669428
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
19. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
